Skip to main content
 

X

News

BeiGene News

See all News

  • October 6, 2020
    BioAtla and BeiGene Revise Global Development and Commercialization Agreement for Novel Conditionally Active Biologic CTLA-4 Candidate BA3071

    BioAtla and BeiGene Revise Global Development and Commercialization Agreement for Novel Conditionally Active Biologic CTLA-4 Candidate BA3071

  • September 21, 2020
    Leap Therapeutics and BeiGene Announce First Patient Dosed in Study of DKN-01 in Combination with Tislelizumab for the Treatment of Metastatic Gastric or Gastroesophageal Junction Cancer

    Leap Therapeutics and BeiGene Announce First Patient Dosed in Study of DKN-01 in Combination with Tislelizumab for the Treatment of Metastatic Gastric or Gastroesophageal Junction Cancer

  • September 17, 2020
    BeiGene Presents Data at ESMO Virtual Congress 2020 on Phase 3 Trial of Tislelizumab in First-Line Non-Squamous Non-Small Cell Lung Cancer and Phase 2 Trial of Pamiparib in Advanced Ovarian Cancer

    BeiGene Presents Data at ESMO Virtual Congress 2020 on Phase 3 Trial of Tislelizumab in First-Line Non-Squamous Non-Small Cell Lung Cancer and Phase 2 Trial of Pamiparib in Advanced Ovarian Cancer

  • September 10, 2020
    BeiGene to Present at the Morgan Stanley 18th Annual Global Healthcare Conference

    BeiGene to Present at the Morgan Stanley 18th Annual Global Healthcare Conference

  • September 9, 2020
    BeiGene Announces Acceptance and Priority Review by Health Canada of New Drug Submission for BRUKINSA® (zanubrutinib) in Waldenström’s Macroglobulinemia

    BeiGene Announces Acceptance and Priority Review by Health Canada of New Drug Submission for BRUKINSA® (zanubrutinib) in Waldenström’s Macroglobulinemia

  • September 4, 2020
    BeiGene Announces Inclusion of Its Shares in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs

    BeiGene Announces Inclusion of Its Shares in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs

  • BeiGene Facts
  • 2010Founded
  • NASDAQ: BGNE  
    HKEX: 06160
    Listings
  • 6Internally Developed
    Clinical Candidates
  • 5Marketed
    Products
    in China
  • 1Approved
    products
    in the U.S.
  • 4200+Global Team
story
 
BeiGene Co-Founders, John V. Oyler and Xiaodong Wang, Ph.D.

2010

2010

  • BeiGene was founded as a research and development company
Immuno-oncology Therapies

2012

2012

  • Began work on an anti-PD-1 antibody and a BTK inhibitor
Clinical Researcher

2014

2014

  • Started clinical trials of pamiparib and zanubrutinib
First China biotech to go public on the Nasdaq

2016

2016

  • Went public on the Nasdaq, with $182 million initial public offering
BeiGene expands global operations

2018

2018

  • Established first European office in Switzerland
  • 50+ ongoing or planned clinical trials
2019

2019

2019

  • Received first FDA approval for BRUKINSA™ (zanubrutinib)
  • Received first approval for tislelizumab in China

Our Story

Breaking Boundaries From the Beginning

From our start in Beijing with a handful of scientists and developers, to today, with a global team, a rich pipeline, strong partnerships, and commercial products. We have accomplished so much in a short time, and yet there is so much still to do.

Our Story

Partnering

Partnerships that Extend Around the Globe

BeiGene is the partner of choice in China for development and commercialization. Read more about our current partnerships and opportunities to build business relationships.

Partners

ZymeworksBioAtla LogoLeapSeagen_LogoAmbrx LogoMirati LogoMEI logoAmgen logoEUSA LogoAssembly Bio LogoChi-Med LogoBio-Thera LogoSinglomics Logo

Our Patients

Our Commitment to Patients

At BeiGene we are focused not only on the underserved global cancer patient population, but also on individual people fighting their illnesses.

Patients

Careers
 

Careers

Join Our
Team

We’re looking for highly motivated colleagues who can collaborate with us as we build a company that will have a lasting impact on the global fight against cancer.

Careers